FDA Approves xT CDx, a NGS-Based in Vitro Diagnostic Device
The FDA has approved xT CDx, a 648-gene next-generation sequencing assay for solid tumor profiling, and companion diagnostic for patients with colorectal cancer.
Eric Lefkofsky Tempus Labs Inc Companion Diagnostics Xt Cdx Next Generation Sequencing Diagnostic Device
Source: onclive.com